Join us as leading experts discuss key data from the Plenary, Late-breaking and top oral sessions across each major disease area at ASCO 2026
touchONCOLOGY coverage of ASCO 2026
2026 American Society of Clinical Oncology (ASCO) Annual Meeting brought together the global oncology community to unveil the latest practice-shaping advances in cancer care. From plenary and late-breaking trial results to novel therapeutics, translational science and emerging technologies, the meeting delivered a vast volume of data across every tumour type. In this expert-led round-up, leading specialists distil the most important data and key takeaways from across each disease area, from breast to blood cancers, offering an essential guide to the studies set to shape the future of oncology.
Plenary late-breaking abstracts
The five selected Plenary late-breaking abstracts at ASCO 2026 showcased breakthroughs in prostate cancer, sarcoma, lung cancer and pancreatic cancer. We bring you the key takeaways from the PROTEUS, SARC041, LIBRETTO-432, HARMONi-6, and RASolute 302 studies.
→ Read: ASCO 2026 Plenary late-breaking abstracts: Key takeaways
Bladder cancer
“Few fields in oncology are moving as rapidly as bladder cancer. From perioperative treatment to metastatic disease, the consistent message from ASCO 2026 was that deeper responses are translating into longer survival, and increasingly into the possibility of longer-term disease control.” Prof Axel S Merseburger
→ Read: Bladder cancer at ASCO 2026: The breakthroughs that matter most
Breast cancer
“ASCO 2026 was a highly interesting and a strategically important meeting for breast cancer. There was certainly a lot that will shape the future, however there was little that immediately changes practice compared to previous landmark years.” Dr Rupert Bartsch
→ Read: Breast Cancer at ASCO 2026: Six key insights
→ Read: ASCENT-04: Further data supports front-line sacituzumab govitecan for PD-L1-positive advanced triple-negative breast cancer
Gastrointestinal oncology
From ctDNA-guided adjuvant therapy to next-generation targeted combinations and intensified perioperative strategies, ASCO 2026 delivered late-breaking GI cancer data shaping the future of precision care. Here, we highlight six of the most important studies.
→ Read: Gastrointestinal oncology at ASCO 2026: Six key late-breakers
Kidney cancer
“The key message at ASCO 2026 was clear: the future of RCC is not simply about adding more therapies, but about identifying the right patients for the right treatment. While adjuvant immunotherapy remains under scrutiny, advances in ctDNA and microbiome research suggest that a more personalized approach to kidney cancer is finally coming into view.” Prof Axel S Merseburger
→ Read: Kidney cancer at ASCO 2026: The studies redefining the field
Lung cancer
“ASCO 2026 highlighted a clear shift in thoracic oncology: from proof-of-concept toward questions of optimization, sequencing and global applicability” Dr Federico Monaca
→ Read: Lung cancer at ASCO 2026: Key takeaways
Hematological malignancies
“This year at ASCO 2026 there were several pivotal studies presented for lymphoma. These studies will help continue to shape the future of treatment across the spectrum of indolent, intermediate or aggressive lymphoma” Dr Tycel Phillips
→ Read: Lymphoma at ASCO 2026: Six key abstracts
→ Read: SUCCESSOR-2: Mezigdomide combination improves progression-free survival in relapsed and refractory multiple myeloma
Neuro-oncology
“In neuro-oncology at ASCO 2026 we saw a mix of practice-informing evidence and emerging innovation. Several large studies clarified the optimal utilization of existing therapeutics and smaller, early-phase trials fostered hope for novel approaches in the future.” Dr Rimas Lukas
→ Read: Neuro-oncology at ASCO 2026: What did we learn?
→ Read: INDIGO: Follow-up data supports sustained benefit of vorasidenib in IDH-mutant grade 2 glioma
Prostate cancer
From treatment intensification to radiotherapy innovation, this year’s ASCO 2026 late-breaking abstracts tackled some of the biggest questions in the field of prostate cancer.
→ Read: Prostate cancer at ASCO 2026: Which late-breakers could change practice?
→ Watch: Upfront PARP inhibition in mHSPC: Key findings from the TALAPRO-3 trial
Skin cancer
ARTEMIS-UC is a phase 2, double-blind, placebo-controlled study investigating tulisokibart in participants with moderate-to-severe ulcerative colitis (UC). In this Q&A, we spoke with Dr Christopher Ma explores the mechanism of action of tulisokibart, the aims, design and key findings from the phase 2 ARTEMIS-UC study, and the significance of the Week 50 results.
→ Read: Skin cancer at ASCO 2026: Five late-breaking studies
New insights are added regularly, covering a broad range of subspecialties and evolving clinical scenarios. Sign up below for Free Access to the latest clinical updates in your specialty!
This content has been developed independently by Touch Medical Media for touchONCOLOGY. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Cite: ASCO 2026 complete round-up: Discover the most important data by disease area. touchONCOLOGY. 2 July 2026.
Editor: Sophie Nickelson, Editorial Director
